問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

楊靜宜

Recruiting

List

25Cases

2023-05-31 - 2027-08-21

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2023-07-01 - 2029-08-10

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2025-06-30 - 2027-07-28

Phase III

Active
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Lebrikizumab in Adult and Adolescent Participants with Moderate-to-Severe Atopic Hand and Foot Dermatitis

  • Condition/Disease

    Atopic Hand and Foot Dermatitis

  • Test Drug

    異可適注射劑 (EBGLYSS Injection)

Participate Sites
7Sites

Recruiting7Sites

2024-05-31 - 2027-05-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2024-09-01 - 2027-12-30

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

2024-12-01 - 2027-11-30

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Recruiting10Sites

2026-05-01 - 2027-12-31

Phase II

Active
A Phase 2b, Randomized, Placebo‑Controlled Study with Long-term Re-Treatment to Evaluate the Efficacy, Safety, and Tolerability of CBL‑514 Injection for Reducing Abdominal Subcutaneous Fat

  • Condition/Disease

    Subcutaneous Fat

  • Test Drug

    CBL-514

Participate Sites
8Sites

Recruiting8Sites

2025-02-01 - 2025-08-05

Completed
A multinational, multicenter, double-blind, placebo-controlled phase 2 trial evaluating the efficacy and safety of SAR444656 in adult subjects with moderate to severe atopic dermatitis.

  • Condition/Disease

    The study aimed to evaluate the efficacy of SAR444656 compared to placebo in treating AD lesions in adult subjects with moderate to severe AD. • Percentage change in EASI from baseline to week 16.

  • Test Drug

    SAR444656

Participate Sites
4Sites

Recruiting4Sites

2023-04-01 - 2031-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2025-03-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB